On December 10, Glorious Capital reported that Hebei Changshan Biochemical Pharmaceutical rose over 10%, while Hybio Pharmaceutical, Saint Now Biotech, Hongyuan Pharmaceutical, and Brightgene Bio-Medical Technology Co., Ltd. also saw increases. In news, the oral version of Semaglutide launched its nationwide pre-sale on Meituan at 21:00 on December 9. At the same time, the peptide Tirzepatide, recognized by the Industry as Semaglutide's "strongest competitor," began its initial appointment booking on Meituan; users in certain areas can book local clinics for weight management, and it is reported that a home delivery service will open for reservations within a week.